Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions

NCT00407355 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Macular Edema
Retinal Vein Occlusion

Interventions

DRUG: Intravitreal injection of ranibizumab .3 dose
DRUG: Intravitreal injection of Ranibizumab .5 dose

Sponsor

Peter A Campochiaro, MD

Collaborators

[object Object]